# US 2025/0205368 A1 · Intrathecal Delivery of Recombinant Adeno-Associated Virus 9

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205368 A1
- Document ID: US20250205368A1
- Status: Published application
- Kind: A1
- Application number: 19/038,011
- Filed: 2025-01-27
- Published: 2025-06-26
- Earliest claimed: 2012-08-01
- Assignees: Nationwide Children's Hospital, Inc.; Ohio State Innovation Foundation
- Applicants: Nationwide Children's Hospital; Ohio State Innovation Foundation
- Inventors: Brian K. Kaspar; Arthur Burghes; Paul Porensky
- Web page: https://patentgrep.com/patent/US20250205368A1

## CPC

- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61K 38/1709: {from mammals}
- A61K 48/0008: {characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition}
- A61K 49/0438: {Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/47: from mammals
- C12N 15/86: Viral vectors
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present invention relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated. for example. for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders.

## Claims

### Claim 1

A method of delivering a polynucleotide to the central nervous system of a patient in need thereof comprising intrathecal delivery of a rAAV9 and a non-ionic, low-osmolar contrast agent to the patient, wherein the rAAV9 comprises a self-complementary genome including the polynucleotide.

### Claim 2 (depends on 1)

The method of claim 1 wherein the polynucleotide is delivered to the brain.

### Claim 3 (depends on 1)

The method of claim 1 wherein the polynucleotide is delivered to the spinal cord.

### Claim 4 (depends on 1)

The method of claim 1 wherein the polynucleotide is delivered to a glial cell.

### Claim 5 (depends on 4)

The method of claim 4 wherein the glial cell is an astrocyte.

### Claim 6 (depends on 1)

The method of claim 1 wherein the polynucleotide is delivered to a lower motor neuron.

### Claim 7 (depends on 1)

The method of claim 1 wherein the non-ionic, low-osmolar contrast agent is iobitridol, iohexol, iomeprol, iopamidol, iopentol, iopromide, ioversol or ioxilan.

### Claim 8 (depends on 7)

The method of claim 7 wherein the non-ionic, low-osmolar contrast agent is iohexol.

### Claim 9 (depends on 1)

The method of claim 1 wherein the polynucleotide is a neuronal ceroid lipofuscinosis 1 (CLN1) gene polynucleotide.

### Claim 10

A method of treating a lysosomal storage disorder in a patient in need thereof comprising intrathecal delivery of a rAAV9 and a non-ionic, low-osmolar contrast agent to the patient, wherein the rAAV9 comprises a self-complementary genome including a therapeutic polynucleotide.

### Claim 11 (depends on 10)

The method of claim 10 wherein the lysosomal storage disorder is CLN1 disease.

### Claim 12 (depends on 10)

The method of claim 10 wherein the polynucleotide is delivered to the brain.

### Claim 13 (depends on 10)

The method of claim 10 wherein the polynucleotide is delivered to the spinal cord.

### Claim 14 (depends on 10)

The method of claim 10 wherein the polynucleotide is delivered to a glial cell.

### Claim 15 (depends on 10)

The method of claim 10 wherein the polynucleotide is delivered to a lower motor neuron.

### Claim 16 (depends on 10)

The method of claim 10 wherein the non-ionic, low-osmolar contrast agent is iobitridol, iohexol, iomeprol, iopamidol, iopentol, iopromide, ioversol or ioxilan.

### Claim 17 (depends on 16)

The method of claim 16 wherein the non-ionic, low-osmolar contrast agent is iohexol.

### Claim 18 (depends on 10)

The method of claim 10 wherein the patient is put in the Trendelenberg position after intrathecal delivery of the rAAV9.
